USA - NASDAQ:COSM - US2214133058 - Common Stock
The current stock price of COSM is 0.9156 USD. In the past month the price decreased by -14.43%. In the past year, price increased by 27.24%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| MCK | MCKESSON CORP | 24.24 | 100.93B | ||
| COR | CENCORA INC | 21.69 | 65.15B | ||
| CAH | CARDINAL HEALTH INC | 19.88 | 38.92B | ||
| HSIC | HENRY SCHEIN INC | 13.64 | 7.71B | ||
| AHCO | ADAPTHEALTH CORP | 30.35 | 1.27B | ||
| AHG | AKSO HEALTH GROUP | N/A | 900.69M | ||
| OMI | OWENS & MINOR INC | 3.75 | 423.28M | ||
| WGRX | WELLGISTICS HEALTH INC | N/A | 74.97M | ||
| ATPC | AGAPE ATP CORP | N/A | 63.01M | ||
| VRAX | VIRAX BIOLABS GROUP LTD | N/A | 2.53M | ||
| POM | POMDOCTOR LTD - ADR | N/A | 556.67M |
Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. The firm owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. The company also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
COSMOS HEALTH INC
5 Agiou Georgiou, Pilea
Thessaloniki ILLINOIS GR
Employees: 149
Phone: 303125363102
Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. The firm owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. The company also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
The current stock price of COSM is 0.9156 USD. The price decreased by -10.24% in the last trading session.
COSM does not pay a dividend.
COSM has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
The Revenue of COSMOS HEALTH INC (COSM) is expected to grow by 25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
COSMOS HEALTH INC (COSM) has a market capitalization of 27.66M USD. This makes COSM a Nano Cap stock.
ChartMill assigns a technical rating of 6 / 10 to COSM. When comparing the yearly performance of all stocks, COSM is one of the better performing stocks in the market, outperforming 73.69% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to COSM. COSM may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months COSM reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 51.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.88% | ||
| ROE | -82.22% | ||
| Debt/Equity | 0.26 |
7 analysts have analysed COSM and the average price target is 3.06 USD. This implies a price increase of 234.21% is expected in the next year compared to the current price of 0.9156.
For the next year, analysts expect an EPS growth of 101.28% and a revenue growth 25% for COSM